

- [processes/procedure-manual/procedure-manual-appendix-vi-criteria-assessing-internal-validity-individual-studies](#)
252. Turner JM. Intravenous Contrast is Associated with AKI in Patients with Stage 1-3 CKD: CON. *Kidney360*. May 1 2024;5(5):648-650. doi:10.34067/kid.000000000000187
  253. Delgado C, Baweja M, Crews DC, et al. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. *J Am Soc Nephrol*. Dec 1 2021;32(12):2994-3015. doi:10.1681/asn.2021070988
  254. Shlipak MG, Mattes MD, Peralta CA. Update on cystatin C: incorporation into clinical practice. *Am J Kidney Dis*. Sep 2013;62(3):595-603. doi:10.1053/j.ajkd.2013.03.027
  255. Pharmacokinetics in Patients with Impaired Renal Function - Study Design, Data Analysis, and Impact on Dosing: Guidance for Industry (2024).
  256. St Peter WL, Bzowyckj AS, Anderson-Haag T, et al. Moving forward from Cockcroft-Gault creatinine clearance to race-free estimated glomerular filtration rate to improve medication-related decision-making in adults across healthcare settings: A consensus of the National Kidney Foundation Workgroup for Implementation of Race-Free eGFR-Based Medication-Related Decisions. *Am J Health Syst Pharm*. Nov 18 2024;doi:10.1093/ajhp/zxae317
  257. Bouquegneau A, Vidal-Petiot E, Moranne O, et al. Creatinine-based equations for the adjustment of drug dosage in an obese population. *Br J Clin Pharmacol*. Feb 2016;81(2):349-61. doi:10.1111/bcp.12817
  258. Donker EM, Bet P, Nurmohamed A, et al. Estimation of glomerular filtration rate for drug dosing in patients with very high or low body mass index. *Clin Transl Sci*. Sep 2022;15(9):2206-2217. doi:10.1111/cts.13354
  259. Titan S, Miao S, Tighiouart H, et al. Performance of Indexed and Nonindexed Estimated GFR. *Am J Kidney Dis*. Sep 2020;76(3):446-449. doi:10.1053/j.ajkd.2020.04.010
  260. Rolland AL, Garnier AS, Meunier K, Drablier G, Briet M. Drug-Induced Acute Kidney Injury: A Study from the French Medical Administrative and the French National Pharmacovigilance Databases Using Capture-Recapture Method. *J Clin Med*. Jan 6 2021;10(2)doi:10.3390/jcm10020168
  261. Ehrmann S, Helms J, Joret A, et al. Nephrotoxic drug burden among 1001 critically ill patients: impact on acute kidney injury. *Ann Intensive Care*. Sep 23 2019;9(1):106. doi:10.1186/s13613-019-0580-1
  262. Kurani S, Jeffery MM, Thorsteinsdottir B, et al. Use of Potentially Nephrotoxic Medications by U.S. Adults with Chronic Kidney Disease: NHANES, 2011-2016. *J Gen Intern Med*. Apr 2020;35(4):1092-1101. doi:10.1007/s11606-019-05557-8
  263. Dobrek L. A Synopsis of Current Theories on Drug-Induced Nephrotoxicity. *Life (Basel)*. Jan 24 2023;13(2)doi:10.3390/life13020325
  264. Ostermann M, Bellomo R, Burdmann EA, et al. Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. *Kidney Int*. Aug 2020;98(2):294-309. doi:10.1016/j.kint.2020.04.020
  265. Kumar V, Jha V. Community acquired and hospital acquired AKI - two diseases divided by a common definition. *Curr Opin Nephrol Hypertens*. Jul 1 2023;32(4):386-393. doi:10.1097/mnh.0000000000000882
  266. FDA Adverse Events Reporting System (FAERS) Public Dashboard. <https://fis.fda.gov/sense/app/95239e26-e0be-42d9-a960-9a5f7f1c25ee/sheet/33a0f68e-845c-48e2-bc81-8141c6aaf772/state/analysis>
  267. Baptista A, Marreiros A, Macedo A, Coelho A. Drug-Associated Acute Kidney Disease: Data From a World Pharmacovigilance Database. *Cureus*. Jul 2024;16(7):e63636. doi:10.7759/cureus.63636